466 related articles for article (PubMed ID: 28925794)
21. Development of stable influenza vaccine powder formulations: challenges and possibilities.
Amorij JP; Huckriede A; Wilschut J; Frijlink HW; Hinrichs WL
Pharm Res; 2008 Jun; 25(6):1256-73. PubMed ID: 18338241
[TBL] [Abstract][Full Text] [Related]
22. Pharmaceutical spray freeze drying.
Wanning S; Süverkrüp R; Lamprecht A
Int J Pharm; 2015 Jul; 488(1-2):136-53. PubMed ID: 25900097
[TBL] [Abstract][Full Text] [Related]
23. The effect of formulation on spray dried Sabin inactivated polio vaccine.
Kanojia G; Ten Have R; Brugmans D; Soema PC; Frijlink HW; Amorij JP; Kersten G
Eur J Pharm Biopharm; 2018 Aug; 129():21-29. PubMed ID: 29787800
[TBL] [Abstract][Full Text] [Related]
24. Spray dried powders for nasal delivery: Process and formulation considerations.
Henriques P; Fortuna A; Doktorovová S
Eur J Pharm Biopharm; 2022 Jul; 176():1-20. PubMed ID: 35568256
[TBL] [Abstract][Full Text] [Related]
25. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.
Vandenheuvel D; Singh A; Vandersteegen K; Klumpp J; Lavigne R; Van den Mooter G
Eur J Pharm Biopharm; 2013 Aug; 84(3):578-82. PubMed ID: 23353012
[TBL] [Abstract][Full Text] [Related]
26. Intranasal delivery of thin-film freeze-dried monoclonal antibodies using a powder nasal spray system.
Yu YS; Xu H; AboulFotouh K; Williams G; Suman J; Sahakijpijarn S; Cano C; Warnken ZN; Wu KC; Williams RO; Cui Z
Int J Pharm; 2024 Mar; 653():123892. PubMed ID: 38350499
[TBL] [Abstract][Full Text] [Related]
27. Acoustic levitation as a screening method for excipient selection in the development of dry powder vaccines.
Morgan BA; Xing Z; Cranston ED; Thompson MR
Int J Pharm; 2019 May; 563():71-78. PubMed ID: 30930189
[TBL] [Abstract][Full Text] [Related]
28. Dried influenza vaccines: over the counter vaccines.
Saluja V; Hinrichs WL; Frijlink HW
Hum Vaccin; 2010 Oct; 6(10):854-6. PubMed ID: 20930565
[TBL] [Abstract][Full Text] [Related]
29. Microparticle encapsulation of a tuberculosis subunit vaccine candidate containing a nanoemulsion adjuvant via spray drying.
Gomez M; Archer M; Barona D; Wang H; Ordoubadi M; Bin Karim S; Carrigy NB; Wang Z; McCollum J; Press C; Gerhardt A; Fox CB; Kramer RM; Vehring R
Eur J Pharm Biopharm; 2021 Jun; 163():23-37. PubMed ID: 33753213
[TBL] [Abstract][Full Text] [Related]
30. Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration.
Patil HP; Murugappan S; de Vries-Idema J; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
Eur J Pharm Biopharm; 2015 Jun; 93():231-41. PubMed ID: 25896446
[TBL] [Abstract][Full Text] [Related]
31. The impact of drying method and formulation on the physical properties and stability of methionyl human growth hormone in the amorphous solid state.
Abdul-Fattah AM; Lechuga-Ballesteros D; Kalonia DS; Pikal MJ
J Pharm Sci; 2008 Jan; 97(1):163-84. PubMed ID: 17722086
[TBL] [Abstract][Full Text] [Related]
32. Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy.
Li HY; Neill H; Innocent R; Seville P; Williamson I; Birchall JC
J Drug Target; 2003 Aug; 11(7):425-32. PubMed ID: 15203931
[TBL] [Abstract][Full Text] [Related]
33. Development and testing of particulate formulations for the nasal delivery of antibodies.
Kaye RS; Purewal TS; Alpar OH
J Control Release; 2009 Apr; 135(2):127-35. PubMed ID: 19059291
[TBL] [Abstract][Full Text] [Related]
34. Development of a Freeze-Dried, Heat-Stable Influenza Subunit Vaccine Formulation.
Flood A; Estrada M; McAdams D; Ji Y; Chen D
PLoS One; 2016; 11(11):e0164692. PubMed ID: 27851765
[TBL] [Abstract][Full Text] [Related]
35. Spray drying of a poorly water-soluble drug nanosuspension for tablet preparation: formulation and process optimization with bioavailability evaluation.
Sun W; Ni R; Zhang X; Li LC; Mao S
Drug Dev Ind Pharm; 2015 Jun; 41(6):927-33. PubMed ID: 24785575
[TBL] [Abstract][Full Text] [Related]
36. Spray drying OZ439 nanoparticles to form stable, water-dispersible powders for oral malaria therapy.
Ristroph KD; Feng J; McManus SA; Zhang Y; Gong K; Ramachandruni H; White CE; Prud'homme RK
J Transl Med; 2019 Mar; 17(1):97. PubMed ID: 30902103
[TBL] [Abstract][Full Text] [Related]
37. Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole.
Kumar S; Shen J; Burgess DJ
J Control Release; 2014 Oct; 192():95-102. PubMed ID: 25009979
[TBL] [Abstract][Full Text] [Related]
38. Spray-coating for biopharmaceutical powder formulations: beyond the conventional scale and its application.
Maa YF; Ameri M; Rigney R; Payne LG; Chen D
Pharm Res; 2004 Mar; 21(3):515-23. PubMed ID: 15070104
[TBL] [Abstract][Full Text] [Related]
39. Formulating monoclonal antibodies as powders for reconstitution at high concentration using spray drying: Models and pitfalls.
Batens M; Massant J; Teodorescu B; Van den Mooter G
Eur J Pharm Biopharm; 2018 Jun; 127():407-422. PubMed ID: 29499299
[TBL] [Abstract][Full Text] [Related]
40. Influences of process and formulation parameters on powder flow properties and immunogenicity of spray dried polymer particles entrapping recombinant pneumococcal surface protein A.
Anish C; Upadhyay AK; Sehgal D; Panda AK
Int J Pharm; 2014 May; 466(1-2):198-210. PubMed ID: 24631054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
